Prometheus, Cedars-Sinai Medical Center deal

Prometheus and the center's Tarrot Laboratories business unit partnered to identify genetic or serologic markers associated with clinical response to tumor necrosis factor (TNF) alpha inhibitors for Crohn's disease. The partners will use the markers to develop diagnostics, sharing costs and technology for R&D activities. Prometheus will receive exclusive rights to IP and any tests developed under the deal, and Tarrot will receive undisclosed development milestones, plus royalties. ...